Federal regulators have approved a new oral drug for multiple myeloma that patients can take as early as their first relapse, opening a treatment class that has not previously been available for the disease.
The Food and Drug Administration granted accelerated approval on August 13 to iberdomide, sold by Bristol Myers Squibb as Zenbexus, in combination with daratumumab and hyaluronidase-fihj and dexamethasone. The combination is for adults with multiple myeloma who have already received at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory agent.
